The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Lung Cancer Vaccine Market Research Report 2025
Synopsis
The global Lung Cancer Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Lung Cancer Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Lung Cancer Vaccine.
Report Scope
The Lung Cancer Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Lung Cancer Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Lung Cancer Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GlaxoSmithKline
Oncothyreon Incorporation
Eli Lily
ImClone Systems
Boehringer Ingelheim
Merck
Ono Pharmaceutical
CureVac
Segment by Type
Subunit Vaccines
Live Attenuated Vaccines
Conjugate Vaccines
Inactivated Vaccines
Recombinant Vector Vaccines
Segment by Application
Man
Woman
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Lung Cancer Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Lung Cancer Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Lung Cancer Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Lung Cancer Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Lung Cancer Vaccine.
Report Scope
The Lung Cancer Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Lung Cancer Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Lung Cancer Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
GlaxoSmithKline
Oncothyreon Incorporation
Eli Lily
ImClone Systems
Boehringer Ingelheim
Merck
Ono Pharmaceutical
CureVac
Segment by Type
Subunit Vaccines
Live Attenuated Vaccines
Conjugate Vaccines
Inactivated Vaccines
Recombinant Vector Vaccines
Segment by Application
Man
Woman
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Lung Cancer Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Lung Cancer Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Lung Cancer Vaccine Market Overview
1.1 Product Overview and Scope of Lung Cancer Vaccine
1.2 Lung Cancer Vaccine Segment by Type
1.2.1 Global Lung Cancer Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 Subunit Vaccines
1.2.3 Live Attenuated Vaccines
1.2.4 Conjugate Vaccines
1.2.5 Inactivated Vaccines
1.2.6 Recombinant Vector Vaccines
1.3 Lung Cancer Vaccine Segment by Application
1.3.1 Global Lung Cancer Vaccine Market Value by Application: (2024-2030)
1.3.2 Man
1.3.3 Woman
1.4 Global Lung Cancer Vaccine Market Size Estimates and Forecasts
1.4.1 Global Lung Cancer Vaccine Revenue 2019-2030
1.4.2 Global Lung Cancer Vaccine Sales 2019-2030
1.4.3 Global Lung Cancer Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Lung Cancer Vaccine Market Competition by Manufacturers
2.1 Global Lung Cancer Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Lung Cancer Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Lung Cancer Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Lung Cancer Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Lung Cancer Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Lung Cancer Vaccine, Product Type & Application
2.7 Lung Cancer Vaccine Market Competitive Situation and Trends
2.7.1 Lung Cancer Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Lung Cancer Vaccine Players Market Share by Revenue
2.7.3 Global Lung Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Lung Cancer Vaccine Retrospective Market Scenario by Region
3.1 Global Lung Cancer Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Lung Cancer Vaccine Global Lung Cancer Vaccine Sales by Region: 2019-2030
3.2.1 Global Lung Cancer Vaccine Sales by Region: 2019-2024
3.2.2 Global Lung Cancer Vaccine Sales by Region: 2025-2030
3.3 Global Lung Cancer Vaccine Global Lung Cancer Vaccine Revenue by Region: 2019-2030
3.3.1 Global Lung Cancer Vaccine Revenue by Region: 2019-2024
3.3.2 Global Lung Cancer Vaccine Revenue by Region: 2025-2030
3.4 North America Lung Cancer Vaccine Market Facts & Figures by Country
3.4.1 North America Lung Cancer Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Lung Cancer Vaccine Sales by Country (2019-2030)
3.4.3 North America Lung Cancer Vaccine Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Lung Cancer Vaccine Market Facts & Figures by Country
3.5.1 Europe Lung Cancer Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Lung Cancer Vaccine Sales by Country (2019-2030)
3.5.3 Europe Lung Cancer Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Lung Cancer Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Lung Cancer Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Lung Cancer Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Lung Cancer Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Lung Cancer Vaccine Market Facts & Figures by Country
3.7.1 Latin America Lung Cancer Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Lung Cancer Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Lung Cancer Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Lung Cancer Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Lung Cancer Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Lung Cancer Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Lung Cancer Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Lung Cancer Vaccine Sales by Type (2019-2030)
4.1.1 Global Lung Cancer Vaccine Sales by Type (2019-2024)
4.1.2 Global Lung Cancer Vaccine Sales by Type (2025-2030)
4.1.3 Global Lung Cancer Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Lung Cancer Vaccine Revenue by Type (2019-2030)
4.2.1 Global Lung Cancer Vaccine Revenue by Type (2019-2024)
4.2.2 Global Lung Cancer Vaccine Revenue by Type (2025-2030)
4.2.3 Global Lung Cancer Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Lung Cancer Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Lung Cancer Vaccine Sales by Application (2019-2030)
5.1.1 Global Lung Cancer Vaccine Sales by Application (2019-2024)
5.1.2 Global Lung Cancer Vaccine Sales by Application (2025-2030)
5.1.3 Global Lung Cancer Vaccine Sales Market Share by Application (2019-2030)
5.2 Global Lung Cancer Vaccine Revenue by Application (2019-2030)
5.2.1 Global Lung Cancer Vaccine Revenue by Application (2019-2024)
5.2.2 Global Lung Cancer Vaccine Revenue by Application (2025-2030)
5.2.3 Global Lung Cancer Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Lung Cancer Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 GlaxoSmithKline
6.1.1 GlaxoSmithKline Corporation Information
6.1.2 GlaxoSmithKline Description and Business Overview
6.1.3 GlaxoSmithKline Lung Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 GlaxoSmithKline Lung Cancer Vaccine Product Portfolio
6.1.5 GlaxoSmithKline Recent Developments/Updates
6.2 Oncothyreon Incorporation
6.2.1 Oncothyreon Incorporation Corporation Information
6.2.2 Oncothyreon Incorporation Description and Business Overview
6.2.3 Oncothyreon Incorporation Lung Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Oncothyreon Incorporation Lung Cancer Vaccine Product Portfolio
6.2.5 Oncothyreon Incorporation Recent Developments/Updates
6.3 Eli Lily
6.3.1 Eli Lily Corporation Information
6.3.2 Eli Lily Description and Business Overview
6.3.3 Eli Lily Lung Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Eli Lily Lung Cancer Vaccine Product Portfolio
6.3.5 Eli Lily Recent Developments/Updates
6.4 ImClone Systems
6.4.1 ImClone Systems Corporation Information
6.4.2 ImClone Systems Description and Business Overview
6.4.3 ImClone Systems Lung Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 ImClone Systems Lung Cancer Vaccine Product Portfolio
6.4.5 ImClone Systems Recent Developments/Updates
6.5 Boehringer Ingelheim
6.5.1 Boehringer Ingelheim Corporation Information
6.5.2 Boehringer Ingelheim Description and Business Overview
6.5.3 Boehringer Ingelheim Lung Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Boehringer Ingelheim Lung Cancer Vaccine Product Portfolio
6.5.5 Boehringer Ingelheim Recent Developments/Updates
6.6 Merck
6.6.1 Merck Corporation Information
6.6.2 Merck Description and Business Overview
6.6.3 Merck Lung Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Merck Lung Cancer Vaccine Product Portfolio
6.6.5 Merck Recent Developments/Updates
6.7 Ono Pharmaceutical
6.6.1 Ono Pharmaceutical Corporation Information
6.6.2 Ono Pharmaceutical Description and Business Overview
6.6.3 Ono Pharmaceutical Lung Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Ono Pharmaceutical Lung Cancer Vaccine Product Portfolio
6.7.5 Ono Pharmaceutical Recent Developments/Updates
6.8 CureVac
6.8.1 CureVac Corporation Information
6.8.2 CureVac Description and Business Overview
6.8.3 CureVac Lung Cancer Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 CureVac Lung Cancer Vaccine Product Portfolio
6.8.5 CureVac Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Lung Cancer Vaccine Industry Chain Analysis
7.2 Lung Cancer Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Lung Cancer Vaccine Production Mode & Process
7.4 Lung Cancer Vaccine Sales and Marketing
7.4.1 Lung Cancer Vaccine Sales Channels
7.4.2 Lung Cancer Vaccine Distributors
7.5 Lung Cancer Vaccine Customers
8 Lung Cancer Vaccine Market Dynamics
8.1 Lung Cancer Vaccine Industry Trends
8.2 Lung Cancer Vaccine Market Drivers
8.3 Lung Cancer Vaccine Market Challenges
8.4 Lung Cancer Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Lung Cancer Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Lung Cancer Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Lung Cancer Vaccine Market Competitive Situation by Manufacturers in 2023
Table 4. Global Lung Cancer Vaccine Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Lung Cancer Vaccine Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Lung Cancer Vaccine Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Lung Cancer Vaccine Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Lung Cancer Vaccine Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Lung Cancer Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Lung Cancer Vaccine, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Lung Cancer Vaccine, Product Type & Application
Table 12. Global Key Manufacturers of Lung Cancer Vaccine, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Lung Cancer Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Lung Cancer Vaccine as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Lung Cancer Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Lung Cancer Vaccine Sales by Region (2019-2024) & (K Units)
Table 18. Global Lung Cancer Vaccine Sales Market Share by Region (2019-2024)
Table 19. Global Lung Cancer Vaccine Sales by Region (2025-2030) & (K Units)
Table 20. Global Lung Cancer Vaccine Sales Market Share by Region (2025-2030)
Table 21. Global Lung Cancer Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Lung Cancer Vaccine Revenue Market Share by Region (2019-2024)
Table 23. Global Lung Cancer Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Lung Cancer Vaccine Revenue Market Share by Region (2025-2030)
Table 25. North America Lung Cancer Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Lung Cancer Vaccine Sales by Country (2019-2024) & (K Units)
Table 27. North America Lung Cancer Vaccine Sales by Country (2025-2030) & (K Units)
Table 28. North America Lung Cancer Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Lung Cancer Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Lung Cancer Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Lung Cancer Vaccine Sales by Country (2019-2024) & (K Units)
Table 32. Europe Lung Cancer Vaccine Sales by Country (2025-2030) & (K Units)
Table 33. Europe Lung Cancer Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Lung Cancer Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Lung Cancer Vaccine Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Lung Cancer Vaccine Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Lung Cancer Vaccine Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Lung Cancer Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Lung Cancer Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Lung Cancer Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Lung Cancer Vaccine Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Lung Cancer Vaccine Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Lung Cancer Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Lung Cancer Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Lung Cancer Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Lung Cancer Vaccine Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Lung Cancer Vaccine Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Lung Cancer Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Lung Cancer Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Lung Cancer Vaccine Sales (K Units) by Type (2019-2024)
Table 51. Global Lung Cancer Vaccine Sales (K Units) by Type (2025-2030)
Table 52. Global Lung Cancer Vaccine Sales Market Share by Type (2019-2024)
Table 53. Global Lung Cancer Vaccine Sales Market Share by Type (2025-2030)
Table 54. Global Lung Cancer Vaccine Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Lung Cancer Vaccine Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Lung Cancer Vaccine Revenue Market Share by Type (2019-2024)
Table 57. Global Lung Cancer Vaccine Revenue Market Share by Type (2025-2030)
Table 58. Global Lung Cancer Vaccine Price (US$/Unit) by Type (2019-2024)
Table 59. Global Lung Cancer Vaccine Price (US$/Unit) by Type (2025-2030)
Table 60. Global Lung Cancer Vaccine Sales (K Units) by Application (2019-2024)
Table 61. Global Lung Cancer Vaccine Sales (K Units) by Application (2025-2030)
Table 62. Global Lung Cancer Vaccine Sales Market Share by Application (2019-2024)
Table 63. Global Lung Cancer Vaccine Sales Market Share by Application (2025-2030)
Table 64. Global Lung Cancer Vaccine Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Lung Cancer Vaccine Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Lung Cancer Vaccine Revenue Market Share by Application (2019-2024)
Table 67. Global Lung Cancer Vaccine Revenue Market Share by Application (2025-2030)
Table 68. Global Lung Cancer Vaccine Price (US$/Unit) by Application (2019-2024)
Table 69. Global Lung Cancer Vaccine Price (US$/Unit) by Application (2025-2030)
Table 70. GlaxoSmithKline Corporation Information
Table 71. GlaxoSmithKline Description and Business Overview
Table 72. GlaxoSmithKline Lung Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. GlaxoSmithKline Lung Cancer Vaccine Product
Table 74. GlaxoSmithKline Recent Developments/Updates
Table 75. Oncothyreon Incorporation Corporation Information
Table 76. Oncothyreon Incorporation Description and Business Overview
Table 77. Oncothyreon Incorporation Lung Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Oncothyreon Incorporation Lung Cancer Vaccine Product
Table 79. Oncothyreon Incorporation Recent Developments/Updates
Table 80. Eli Lily Corporation Information
Table 81. Eli Lily Description and Business Overview
Table 82. Eli Lily Lung Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Eli Lily Lung Cancer Vaccine Product
Table 84. Eli Lily Recent Developments/Updates
Table 85. ImClone Systems Corporation Information
Table 86. ImClone Systems Description and Business Overview
Table 87. ImClone Systems Lung Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. ImClone Systems Lung Cancer Vaccine Product
Table 89. ImClone Systems Recent Developments/Updates
Table 90. Boehringer Ingelheim Corporation Information
Table 91. Boehringer Ingelheim Description and Business Overview
Table 92. Boehringer Ingelheim Lung Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Boehringer Ingelheim Lung Cancer Vaccine Product
Table 94. Boehringer Ingelheim Recent Developments/Updates
Table 95. Merck Corporation Information
Table 96. Merck Description and Business Overview
Table 97. Merck Lung Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Merck Lung Cancer Vaccine Product
Table 99. Merck Recent Developments/Updates
Table 100. Ono Pharmaceutical Corporation Information
Table 101. Ono Pharmaceutical Description and Business Overview
Table 102. Ono Pharmaceutical Lung Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Ono Pharmaceutical Lung Cancer Vaccine Product
Table 104. Ono Pharmaceutical Recent Developments/Updates
Table 105. CureVac Corporation Information
Table 106. CureVac Description and Business Overview
Table 107. CureVac Lung Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. CureVac Lung Cancer Vaccine Product
Table 109. CureVac Recent Developments/Updates
Table 110. Key Raw Materials Lists
Table 111. Raw Materials Key Suppliers Lists
Table 112. Lung Cancer Vaccine Distributors List
Table 113. Lung Cancer Vaccine Customers List
Table 114. Lung Cancer Vaccine Market Trends
Table 115. Lung Cancer Vaccine Market Drivers
Table 116. Lung Cancer Vaccine Market Challenges
Table 117. Lung Cancer Vaccine Market Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Lung Cancer Vaccine
Figure 2. Global Lung Cancer Vaccine Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Lung Cancer Vaccine Market Share by Type in 2023 & 2030
Figure 4. Subunit Vaccines Product Picture
Figure 5. Live Attenuated Vaccines Product Picture
Figure 6. Conjugate Vaccines Product Picture
Figure 7. Inactivated Vaccines Product Picture
Figure 8. Recombinant Vector Vaccines Product Picture
Figure 9. Global Lung Cancer Vaccine Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 10. Global Lung Cancer Vaccine Market Share by Application in 2023 & 2030
Figure 11. Man
Figure 12. Woman
Figure 13. Global Lung Cancer Vaccine Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Lung Cancer Vaccine Market Size (2019-2030) & (US$ Million)
Figure 15. Global Lung Cancer Vaccine Sales (2019-2030) & (K Units)
Figure 16. Global Lung Cancer Vaccine Average Price (US$/Unit) & (2019-2030)
Figure 17. Lung Cancer Vaccine Report Years Considered
Figure 18. Lung Cancer Vaccine Sales Share by Manufacturers in 2023
Figure 19. Global Lung Cancer Vaccine Revenue Share by Manufacturers in 2023
Figure 20. The Global 5 and 10 Largest Lung Cancer Vaccine Players: Market Share by Revenue in 2023
Figure 21. Lung Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 22. Global Lung Cancer Vaccine Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 23. North America Lung Cancer Vaccine Sales Market Share by Country (2019-2030)
Figure 24. North America Lung Cancer Vaccine Revenue Market Share by Country (2019-2030)
Figure 25. United States Lung Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Canada Lung Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. Europe Lung Cancer Vaccine Sales Market Share by Country (2019-2030)
Figure 28. Europe Lung Cancer Vaccine Revenue Market Share by Country (2019-2030)
Figure 29. Germany Lung Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. France Lung Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. U.K. Lung Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Italy Lung Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Russia Lung Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Asia Pacific Lung Cancer Vaccine Sales Market Share by Region (2019-2030)
Figure 35. Asia Pacific Lung Cancer Vaccine Revenue Market Share by Region (2019-2030)
Figure 36. China Lung Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Japan Lung Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. South Korea Lung Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. India Lung Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Australia Lung Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. China Taiwan Lung Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Indonesia Lung Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Thailand Lung Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Malaysia Lung Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Latin America Lung Cancer Vaccine Sales Market Share by Country (2019-2030)
Figure 46. Latin America Lung Cancer Vaccine Revenue Market Share by Country (2019-2030)
Figure 47. Mexico Lung Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Brazil Lung Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Argentina Lung Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Middle East & Africa Lung Cancer Vaccine Sales Market Share by Country (2019-2030)
Figure 51. Middle East & Africa Lung Cancer Vaccine Revenue Market Share by Country (2019-2030)
Figure 52. Turkey Lung Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Saudi Arabia Lung Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. UAE Lung Cancer Vaccine Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. Global Sales Market Share of Lung Cancer Vaccine by Type (2019-2030)
Figure 56. Global Revenue Market Share of Lung Cancer Vaccine by Type (2019-2030)
Figure 57. Global Lung Cancer Vaccine Price (US$/Unit) by Type (2019-2030)
Figure 58. Global Sales Market Share of Lung Cancer Vaccine by Application (2019-2030)
Figure 59. Global Revenue Market Share of Lung Cancer Vaccine by Application (2019-2030)
Figure 60. Global Lung Cancer Vaccine Price (US$/Unit) by Application (2019-2030)
Figure 61. Lung Cancer Vaccine Value Chain
Figure 62. Lung Cancer Vaccine Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
